Coupland N J
Department of Psychiatry, University of Alberta, Edmonton, Canada.
J Clin Psychiatry. 2001;62 Suppl 1:25-35.
Social phobia is a common and often disabling condition, with an etiology that is not established. There is evidence at several levels for an interplay of biological and psychological processes in social phobia. Genetic studies show that both genetic and environmental factors are important, with evidence pointing to associations with 2 genetic conditions, autism and fragile X syndrome. Behavioral inhibition has emerged as an important precursor to social phobia and possibly to other anxiety disorders. Epidemiologic and clinical studies have suggested that factors within the family environment, such as overprotection, overcontrol, modeling of anxiety, criticism, and in some cases abuse, can play a role in the development of social phobia. During childhood, complex interactions between brain system disturbances that mediate responses to negative social cues and factors in the social setting may lead to the development of a distorted set of internal "blueprints" for social behavior. The impact of severe social anxiety on brain systems that mediate behavioral change may prevent patients from learning better "blueprints." These can be taught through cognitive-behavioral therapies. The effective control of social anxiety with medications enables patients to recover; whether recovery can last after discontinuation of medications may depend on whether a new "blueprint" has been developed and whether stable changes in affected brain systems have occurred. Neuroimaging techniques are at the early stage of identifying abnormalities at the neurotransmitter and systems levels.
社交恐惧症是一种常见且往往会导致功能障碍的病症,其病因尚未明确。有多个层面的证据表明社交恐惧症存在生物和心理过程的相互作用。基因研究表明,基因和环境因素都很重要,有证据指向与两种基因病症——自闭症和脆性X综合征——存在关联。行为抑制已成为社交恐惧症以及可能其他焦虑症的重要先兆。流行病学和临床研究表明,家庭环境中的因素,如过度保护、过度控制、焦虑的示范、批评,以及在某些情况下的虐待,可能在社交恐惧症的发展中起作用。在童年时期,介导对负面社交线索反应的脑系统紊乱与社交环境中的因素之间的复杂相互作用,可能导致形成一套扭曲的社交行为内部“蓝图”。严重社交焦虑对介导行为改变的脑系统的影响,可能会阻止患者学习更好的“蓝图”。这些可以通过认知行为疗法来传授。药物对社交焦虑的有效控制能使患者康复;停药后康复是否能持续,可能取决于是否已形成新的“蓝图”以及受影响的脑系统是否发生了稳定变化。神经成像技术在识别神经递质和系统层面异常方面尚处于早期阶段。